Details for Patent: 8,216,604
✉ Email this page to a colleague
Which drugs does patent 8,216,604 protect, and when does it expire?
Patent 8,216,604 protects LAZANDA and is included in one NDA.
This patent has thirty-five patent family members in twenty-four countries.
Summary for Patent: 8,216,604
| Title: | Method of managing or treating pain |
| Abstract: | A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (C.sub.max) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed. |
| Inventor(s): | Watts; Peter James (Nottingham, GB), Castile; Jonathan David (Nottingham, GB), Lafferty; William Columbus Ian (Leicestershire, GB), Smith; Alan (Nottingham, GB) |
| Assignee: | Archimedes Development Limited (Nottingham, GB) |
| Application Number: | 12/047,388 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 8,216,604
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-001 | Jun 30, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER | ⤷ Sign Up | ||||
| Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-002 | Jun 30, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,216,604
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0300531.1 | Jan 10, 2003 |
International Family Members for US Patent 8,216,604
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1635783 | ⤷ Sign Up | C300653 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1635783 | ⤷ Sign Up | CA 2014 00016 | Denmark | ⤷ Sign Up |
| European Patent Office | 1635783 | ⤷ Sign Up | 300653 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1635783 | ⤷ Sign Up | 122014000024 | Germany | ⤷ Sign Up |
| European Patent Office | 1635783 | ⤷ Sign Up | 132014902242643 | Italy | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
